{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:54:34Z","timestamp":1780048474762,"version":"3.53.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bbr.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T19:36:49Z","timestamp":1546976209000},"page":"109-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs"],"prefix":"10.1016","volume":"362","author":[{"given":"Anat","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-5541","authenticated-orcid":false,"given":"Haim","family":"Einat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2019.01.006_bib0005","series-title":"Encyclopedia of Behavioral Neuroscience","first-page":"436","article-title":"Value of animal models for predicting CNS therapeutic action","author":"McArthur","year":"2010"},{"issue":"10","key":"10.1016\/j.bbr.2019.01.006_bib0010","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbr.2019.01.006_bib0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuroscience.2013.02.045","article-title":"An updated overview of animal models in neuropsychiatry","volume":"240","author":"Razafsha","year":"2013","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2045-5380-1-9","article-title":"Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression","volume":"1","author":"Belzung","year":"2011","journal-title":"Biol. Mood Anxiety Disord."},{"issue":"6","key":"10.1016\/j.bbr.2019.01.006_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0278-5846(86)90051-5","article-title":"Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case","volume":"10","author":"Willner","year":"1986","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2019.01.006_bib0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.neubiorev.2007.05.007","article-title":"Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement","volume":"31","author":"Gould","year":"2007","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0035","first-page":"47","article-title":"New approaches to modeling bipolar disorder","volume":"37","author":"Einat","year":"2003","journal-title":"Psychopharmacol. Bull."},{"issue":"2-3","key":"10.1016\/j.bbr.2019.01.006_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"issue":"6","key":"10.1016\/j.bbr.2019.01.006_bib0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/HRP.0000000000000059","article-title":"New ways of modeling bipolar disorder","volume":"22","author":"Einat","year":"2014","journal-title":"Harv. Rev. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00426631","article-title":"Lithium prevention of amphetamine-induced\u2019 manic\u2019 excitement and of reserpine-induced\u2019 depression\u2019 in mice: possible role of 2-phenylethylamine","volume":"59","author":"Borison","year":"1978","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00421808","article-title":"Lithium and alpha-methyl-p-tyrosine prevent \"manic\" activity in rodents","volume":"36","author":"Davies","year":"1974","journal-title":"Psychopharmacologia"},{"issue":"4","key":"10.1016\/j.bbr.2019.01.006_bib0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF00433745","article-title":"Effects of lithium on behaviour induced by phencyclidine and amphetamine in rats","volume":"78","author":"Fessler","year":"1982","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0278-5846(90)90023-A","article-title":"Effects of lithium on an amphetamine animal model of bipolar disorder","volume":"14","author":"Cappeliez","year":"1990","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0166-4328(00)00318-1","article-title":"Differential sensitivity to lithium\u2019s reversal of amphetamine-induced open-field activity in two inbred strains of mice","volume":"118","author":"Gould","year":"2001","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.bbr.2019.01.006_bib0075","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.pharep.2014.03.013","article-title":"Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in black Swiss mice","volume":"66","author":"Einat","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.04.047","article-title":"Modeling mania: Further validation for black swiss mice as model animals","volume":"223","author":"Hannah-Poquette","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.bbr.2019.01.006_bib0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00429209","article-title":"Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes","volume":"73","author":"Huey","year":"1981","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0090","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0278-5846(84)80031-7","article-title":"Differential effects of carbamazepine and lithium on sensitization and kindling","volume":"8","author":"Post","year":"1984","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s007020200035","article-title":"Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder","volume":"109","author":"Shaldubina","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbr.2019.01.006_bib0100","series-title":"Bipolar Disorders: Basic Mechanisms and Therapeutic Implications","article-title":"Prospects for the development of animal models for the study of bipolar disorder","author":"Einat","year":"2007"},{"key":"10.1016\/j.bbr.2019.01.006_bib0105","series-title":"Animal and Translational Models for CNS Drug Discovery","first-page":"263","article-title":"Developing therapeutics for bipolar disorder: from animal models to the clinic","author":"Large","year":"2008"},{"key":"10.1016\/j.bbr.2019.01.006_bib0110","series-title":"Contemporary Issues in Modeling Psychopharmacology","first-page":"165","article-title":"Animal models of bipolar disorder: from a single episode to progressive cycling models","author":"Einat","year":"2000"},{"issue":"7","key":"10.1016\/j.bbr.2019.01.006_bib0115","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1176\/appi.ajp.157.7.1108","article-title":"Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients","volume":"157","author":"Anand","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2019.01.006_bib0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2165\/00002018-199512020-00007","article-title":"Drug-induced mania","volume":"12","author":"Peet","year":"1995","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.bbr.2019.01.006_bib0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.665","article-title":"Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation","volume":"20","author":"Bell","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bbr.2019.01.006_bib0130","first-page":"25","article-title":"Response to Lithium in bipolar disorder: clinical and genetic findings","volume":"25","author":"Rybakowski","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.bbr.2019.01.006_bib0135","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1017\/S1461145711000885","article-title":"Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials","volume":"14","author":"Vieta","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5309","key":"10.1016\/j.bbr.2019.01.006_bib0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/232336a0","article-title":"Lithium attenuates drug-induced hyperactivity in rats","volume":"232","author":"Cox","year":"1971","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00428028","article-title":"The effect of lithium on amphetamine-induced locomotor stimulation","volume":"59","author":"Berggren","year":"1978","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0150","first-page":"459","article-title":"Chronic lithium treatment and dopamine-mediated behavior","volume":"15","author":"Ebstein","year":"1980","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2019.01.006_bib0155","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.npp.1301254","article-title":"Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium","volume":"32","author":"Gould","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2019.01.006_bib0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1601-183X.2011.00682.x","article-title":"Antidepressant-like responses to lithium in genetically diverse mouse strains","volume":"10","author":"Can","year":"2011","journal-title":"Genes Brain Behav."},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1017\/neu.2013.23","article-title":"Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice","volume":"26","author":"Kara","year":"2014","journal-title":"Acta Neuropsychiatr."},{"issue":"8","key":"10.1016\/j.bbr.2019.01.006_bib0170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0b013e328011b5b2","article-title":"A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder","volume":"17","author":"McQuillin","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"issue":"Article 10","key":"10.1016\/j.bbr.2019.01.006_bib0175","first-page":"1","article-title":"Strain Specific battery of tests for separate behavioral domains of mania","volume":"1","author":"Flaisher-Grinberg","year":"2010","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bbr.2019.01.006_bib0180","first-page":"1","article-title":"Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK-3) inhibitors in a strain specific model of acute mania","volume":"6","author":"Kalinichev","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2019.01.006_bib0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pbb.2014.05.007","article-title":"Beware of your mouse strain; differential effects of lithium on behavioral and neurochemical phenotypes in Harlan ICR mice bred in Israel or the USA","volume":"124C","author":"Sade","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"30","key":"10.1016\/j.bbr.2019.01.006_bib0190","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1523\/JNEUROSCI.4753-03.2004","article-title":"Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium","volume":"24","author":"O\u2019Brien","year":"2004","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000355294","article-title":"Acute Intracerebroventricular Inositol Does Not Reverse the Effect of Chronic Lithium Treatment in the Forced Swim Test","volume":"68","author":"Toker","year":"2013","journal-title":"Neuropsychobiology."},{"issue":"18","key":"10.1016\/j.bbr.2019.01.006_bib0200","first-page":"30699","article-title":"Individual variability in female and male mice in a test-retest protocol of the forced swim test","volume":"23","author":"Kazavchinsky","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"5","key":"10.1016\/j.bbr.2019.01.006_bib0205","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra035354","article-title":"Bipolar disorder","volume":"351","author":"Belmaker","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbr.2019.01.006_bib0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0165-1781(98)00037-7","article-title":"Lithium does not attenuate the effects of D-amphetamine in healthy volunteers","volume":"79","author":"Silverstone","year":"1998","journal-title":"Psychiatry Res."},{"issue":"5-6","key":"10.1016\/j.bbr.2019.01.006_bib0215","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000381785","article-title":"Introducing female black swiss mice: minimal effects of sex in a strain-specific battery of tests for mania-like behavior and response to Lithium","volume":"95","author":"Ene","year":"2015","journal-title":"Pharmacology."},{"key":"10.1016\/j.bbr.2019.01.006_bib0220","first-page":"14","article-title":"The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors","volume":"14","author":"Ene","year":"2015","journal-title":"Behav. Pharmacol."},{"issue":"1-3","key":"10.1016\/j.bbr.2019.01.006_bib0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(95)00292-S","article-title":"Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine","volume":"283","author":"Arnt","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2007-1014476","article-title":"Sensitization and kindling perspectives for the course of affective illness: toward a new treatment with the anticonvulsant carbamazepine","volume":"23","author":"Post","year":"1990","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2019.01.006_bib0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbr.2009.09.040","article-title":"Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder","volume":"207","author":"Dencker","year":"2010","journal-title":"Behav. Brain Res."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818314979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432818314979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:13:22Z","timestamp":1549239202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432818314979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":47,"alternative-id":["S0166432818314979"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2019.01.006","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}